[Ip-health] Gilead's Gold Mine

[James Packard Love]

--
[ Picked text/plain from multipart/alternative ]
*  Last week, Gilead reported its fourth-quarter financial results.
Revenue rose 48% year over year to $900 million, and the company
posted gross margins of 83%. Its key HIV drug franchise sales gained
67% in the quarter, now accounting for more than 70% of all revenue.

http://www.fool.com/investing/general/2007/02/05/gileads-gold-mine.aspx

Gilead's Gold Mine
By Brian Lawler
February 5, 2007

The heart of any pharmaceutical company is the patent portfolio
protecting its drugs. Losing the marketing exclusivity and
monopolistic profits for these pieces of intellectual property can be
ruinous for a drug company's top line. Shareholders of drugmaker
Gilead Sciences (Nasdaq: GILD) won't have these worries for many
years yet, though. Key patents for its top drugs, such as the flu
treatment Tamiflu and the HIV treatment Viread, won't expire until
2016 and 2017, respectively.

Last week, Gilead reported its fourth-quarter financial results.
Revenue rose 48% year over year to $900 million, and the company
posted gross margins of 83%. Its key HIV drug franchise sales gained
67% in the quarter, now accounting for more than 70% of all revenue.
In that light, it's fortunate that Gilead has a lengthy amount of
patent protection on these products.

    [snip]

----------------------------------------------
James Packard Love
Knowledge Ecology International
http://www.keionline.org
james.love@keionline.org
Washington, DC +1.202.332.2670

"If everyone thinks the same: No one thinks." Bill Walton"